Molecular Imaging and Therapy of Prostate Cancer Online Course
Experts from the Society of Nuclear Medicine and Molecular Imaging will speak on the most advanced nuclear medicine technology in both the imaging and therapy of prostate cancer. Prostate specific membrane antigen (PSMA) has been extensively studied as both an imaging and therapeutic target for prostate cancer and therefore also as a theranostic target. PSMA-targeted radiopharmaceuticals for PET imaging and for delivery of therapeutic radiation are now in phase 3 trials and thus may soon be available to greatly expand the role of nuclear medicine in the care of patients with prostate cancer. In-Training Members will receive a discounted price of $99 after login
Target Audience:
The target audience for this activity is radiologists at all training levels are interested in nuclear medicine and prostate imaging.
Goals and Objectives:
After completing the material in this activity, the learner should be able to:
- Describe the capabilities of PSMA-PET imaging for prostate cancer.
- Discuss PSMA targeted PET interpretation.
- Discuss clinical indications for ordering of fluciclovine-PET.
Disclosure of Commercial Interest:
ARRS staff involved with this activity have nothing to disclose. Below is a listing of activity's contributors and planners’ disclosures:
Planners
Speakers
Planners
- G. Whitman has nothing to disclose.
- A. Paladin has nothing to disclose.
Speakers
- S. Galgano receives research support as primary investigator for Blue Earth Diagnostics.
- K. Zukotynski has nothing to disclose.
- P. Kuo receives consulting fees from Imaging Endpoints, Bayer and Novartis. Dr. Kuo is a speaker and consultant for GE Healthcare; a consultant and reader for clinical trials for Konica Minolta; and a principal investigator for Blue Earth Diagnostics.
Member Price:
Free
NonMember Price:
$250.00
Accreditation Statement
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Designation Statement
The ARRS designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.
Date of issuance: June 5, 2020
Date of expiration: June 4, 2026
Estimated time to complete the activity: 2 hour(s)
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Designation Statement
The ARRS designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has determined that physicians not licensed in the US who participate in this CME activity are eligible for AMA PRA Category 1 Credit(s)™.
The American Roentgen Ray Society (ARRS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The ARRS designates this enduring activity for a maximum of 2 AMA PRA Category 1 Credit(s)™ and 2 American Board of Radiology©, MOC Part II, Self-Assessment CME (SA-CME.) Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Date of issuance: June 5, 2020
Date of expiration: June 4, 2026
Estimated time to complete the activity: 2 hour(s)